In medicine, a true breakthrough lies not just in treating a disease, but in buying time. For a long time, the global approach to Type 1 diabetes (T1D) was purely reactive, determined by how effectively the disease was managed after its onset.
In medicine, a true breakthrough lies not just in treating a disease, but in buying time. For a long time, the global approach to Type 1 diabetes (T1D) was purely reactive, determined by how effectively the disease was managed after its onset.
Today, a fundamental shift is occurring in this direction in the United Arab Emirates. Thanks to a national healthcare program that consistently turns ambitions into clinical reality, the country is moving away from managing symptoms in response to a problem. Instead, a new standard of care is being established, focused on preventing and slowing the progression of Type 1 diabetes.
This pursuit of medical progress fully aligns with Sanofi's mission—to achieve scientific miracles to improve people's lives. Over a fifty-year period of collaboration in regional healthcare, tangible clinical successes have been achieved. In May 2024, the UAE became a regional pioneer by implementing the first disease-modifying intervention capable of delaying the clinical stage 3 of Type 1 diabetes.
To understand the scale of this shift, it is necessary to examine the mechanism of the disease. Science shows that an T1D diagnosis is not instantaneous. The autoimmune process begins unnoticed long before the appearance of intense thirst, fatigue, or any physical signs.
This hidden phase, known as stage 2, represents a critical window for intervention. By shifting the focus to the immune system during this period, specialists stop merely treating T1D symptoms; they target the underlying autoimmune process to preserve remaining beta-cell function.
It is important to note that this scientific opportunity now extends to protecting the most vulnerable. Recent global advances in pediatric endocrinology mean that such preemptive treatments are no longer limited to adults. These vital therapies are now being applied to younger populations, starting from the earliest years, as young as one year old.
The implementation of innovative disease-modifying methods for the youngest patients is a clear statement by the medical community. It emphasizes that youth deserves the best modern science has to offer and that there is a shared responsibility to protect their future before the clinical burden begins.
For parents, delaying the onset of T1D stage 3 means fewer nights spent worrying about sudden blood sugar fluctuations. It also provides more opportunities to understand the disease, build confidence, and engage closely with doctors before daily management becomes inevitable. For the healthcare system, this means better preparedness, more structured monitoring, and greater chances of reducing the risk of preventable emergencies.
To fully grasp the impact of this achievement, one must look beyond clinical data and focus on real life. For a family, delaying the onset of T1D stage 3 brings invaluable insulin-free time. It postpones the constant daily demands of glucose monitoring, the fear of severe hypoglycemia, and the heavy emotional burden known as 'diabetes distress.' Most importantly, it grants the child the precious gift of a more continuous childhood.
However, scientific breakthroughs are only effective when integrated into a prepared healthcare system. Since the early stages of T1D are insidious, the only reliable method for identifying those on the brink of the disease is proactive screening for autoantibodies, especially for those with a family history.
Sanofi states its commitment to the Gulf region goes beyond simply providing therapeutics. The company actively collaborates with health authorities, specialists, and patient communities to enhance diagnostic readiness and build the infrastructure needed for early detection to become the standard of care.
The United Arab Emirates possesses all the necessary foundations to be a pioneer in this new era of preemptive autoimmune care. Their vision for a patient-centric and resilient healthcare future is already being realized. Their willingness to engage in public-private partnerships and proven experience in turning ambition into action perfectly match the requirements of this moment.
The story of diabetes treatment in the UAE is one of continuous and inspiring progress. By proactively protecting the health of our children today, we are not just advancing medical science; we are preserving the foundation of this nation's tomorrow. After more than five decades of partnership in regional healthcare, I am very proud that Sanofi is at the forefront of this specific paradigm shift. Together, we are no longer just reacting to Type 1 diabetes; we are anticipating it, delaying it, and building a system that can recognize risks, guide families, and protect children before Type 1 diabetes becomes clinical.
Due to long working hours and intense routines, many professional drivers tend to neglect their own health. In response to this situation, the Ministry of Health implemented the program called 'Now There Are Specialists – Trucker and Trucker'.
This initiative aims to make Unified Health System (SUS) services, such as consultations, exams, and vaccinations, available directly at the Rest and Stopping Points (PPDs) frequented by the category. The central purpose is to reduce barriers to healthcare access and ensure free care. The need for this measure is reinforced by data from the Ministry of Health, which indicates that between 2022 and 2025, 41% of truck drivers registered in Primary Health Care (PHC) did not receive any medical assistance.
The program's mobile units provide completely free assistance and do not require prior scheduling. The structure was designed to fit into the drivers' routine, offering various services, including medical and nursing consultations, vaccination, blood pressure measurement, rapid tests, and laboratory exams with immediate results, electrocardiograms, and minor procedures. If necessary, drivers can be referred to other specialized SUS services.
José Ronaldo Marques da Silva, known as 'Boizinho' and president of the National Union of Truckers (Sinaceg), considers the strategy essential. He stated that health often takes a backseat while the driver meets deadlines and travels across the country. According to him, bringing care to the PPDs is an intelligent approach because it adapts public service to the reality of the category and facilitates the monitoring of professionals who previously lacked such support.
Lack of care for health has generated serious consequences for truck drivers. An epidemiological bulletin issued by the Ministry of Health points out that habits such as inadequate diet, long driving hours, and lack of sufficient rest significantly increase drivers' susceptibility to chronic diseases. Primary Care records highlight notable incidences of arterial hypertension (74,414 cases), diabetes (35,292 records), and mental health problems (21,167 occurrences).
The data also shows an aging process within the category on the roads, with the highest concentration of care occurring in the age group of 50 to 59 years, closely followed by drivers aged 40 to 49.
In a period of just over four months of operation, the program has already demonstrated high unmet demand on the highways with significant numbers. 6,169 attendances were carried out, 8,889 health procedures were performed, 7,087 rapid tests were administered, 2,617 exams were collected, and 933 vaccine doses were given.
Márcio Galdino, regional director of Sinaceg, emphasizes that the benefit goes beyond individual well-being. He points out that transforming stopping points into care locations is a practical solution that expands the reach of SUS and promotes prevention, bringing advantages to both workers and road safety.
Currently, the program operates at strategic points near the usual resting places of truck drivers. The units are available in the cities of Pindamonhangaba (SP), Uruaçu (GO), Ubaporanga (MG), Itatiaia (RJ), Novo Progresso (PA), Seropédica (RJ), Palhoça (SC), and Irati (PR). The service remains accessible indefinitely in these locations; the driver only needs to show up during their scheduled stop.
